PNT News and Press, POINT Biopharma Global Inc. From 12/26/23

2023-12-26 07:43:47 ET More on POINT Biopharma Global Why POINT Biopharma Global Is At Least A Hold On Disappointing Readout POINT Biopharma Global: Why The Market Believes That A Second Bidder May Emerge Eli Lilly POINTs Toward Radiopharmaceutical Ambitions ...

2023-12-20 08:30:00 ET Summary Point Biopharma and Lantheus Holdings released positive topline results for their radioligand therapy in patients with metastatic castration-resistant prostate cancer. The SPLASH trial met its primary endpoint, showing a progression-free survival ben...

2023-12-18 23:16:26 ET Summary Lantheus stock dropped 26% post-SPLASH study, highlighting risks in mCRPC drug development and its strategic alliance with POINT Biopharma. SPLASH trial met primary goals but showed underwhelming overall survival data, affecting investor confidence a...

2023-12-18 14:00:05 ET Summary Eli Lilly and Company wants to acquire POINT Biopharma Global Inc. with a tender offer of $12.5/share, which represented an 87% premium. POINT Biopharma Global is trading at $12.45, just $0.05 above the take-out price, and the tender offer could wrap...

2023-12-18 11:44:54 ET More on Eli Lilly Bubble Warning: Unrealistic Growth Priced In And Multiple Risk Factors For Eli Lilly Eli Lilly and Company (LLY) Presents at 6th Evercore ISI HealthCONx Conference (Transcript) Eli Lilly: Perfectly Priced Healthcare Giant ...

2023-12-18 09:22:49 ET More on Lantheus, POINT Biopharma Global, etc. POINT Biopharma Global: Why The Market Believes That A Second Bidder May Emerge Lantheus Holdings: Huge Catalysts Ahead And Cheap Valuation Lantheus Holdings, Inc. (LNTH) Q3 2023 Earnings Call Tran...

BEDFORD, Mass. and INDIANAPOLIS, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (Lantheus) (NASDAQ: LNTH) and POINT Biopharma Global Inc. (POINT) (NASDAQ: PNT) today announced statistically significant topline results from the pivotal phase 3 SPLASH study evaluating the efficacy a...

Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 22, 2023 PR Newswire INDIANAPOLIS , Dec. 18, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the extension of the expiration of the tender offer to acquire all of the issued and ...

2023-12-08 15:00:12 ET More on the markets S&P 500: New All-Time Highs Before A Major Sell-Off S&P 500 Forecast 2024: Muddling Through Only Thing That Matters Is Price; Nasdaq Has Further To Go - Cestrian Capital Research Money market funds attract mo...

Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 15, 2023 PR Newswire INDIANAPOLIS , Dec. 4, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the extension of the expiration of the tender offer to acquire all of the issued and o...